Vanderbilt Network Lead Academic Participating Site for the NCTN

范德比尔特网络 (Vanderbilt Network) 主导 NCTN 学术参与网站

基本信息

批准号：
10364747
负责人：
JORDAN D BERLIN
金额：
$ 50.76万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-07 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10364747
关键词：
Academic Medical Centers Advanced Malignant Neoplasm Advisory Committees Alabama Antineoplastic Agents Appointment Area Authorship Automobile Driving Award Basic Science Berlin Biology Breast Budgets Cancer Center Cancer Patient Catchment Area Cessation of life Clinical Cancer Center Clinical Investigator Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Collaborations Collection Communities Compassion Comprehensive Cancer Center Conduct Clinical Trials Country Data Death Rate Department chair Development Diagnosis Discipline Discipline of obstetrics Disease Early Detection Research Network Early Therapeutic-Clinical Trials Network Eastern Cooperative Oncology Group Education and Outreach Enrollment Ensure Faculty Funding Goals Grant Growth Gynecology Health Human Image Immunology Immunotherapy Incidence Infection Inflammation Informatics Infrastructure Institutes Institution Institutional Review Boards Jordan Kentucky Knowledge Lead Leadership Malignant Neoplasms Malignant neoplasm of pancreas Manuscripts Medical Medicine Mentors Mentorship Mission Mutation NCI Center for Cancer Research National Cancer Institute National Clinical Trials Network Obesity PD-1/PD-L1 PDL1 inhibitors Patient-Centered Care Patients Phase II/III Clinical Trial Physicians Prevention Prevention education Principal Investigator Process Protocols documentation Radiology Specialty Research Research Activity Research Personnel Research Priority Research Support Resource Sharing Resources Role Science Scientist Services Site System Technology Tennessee Time Tobacco use Training Translational Research Translations United States Universities Work cancer care cancer clinical trial cancer genomics cancer therapy data submission design drug discovery early phase trial evidence base gastrointestinal imaging science improved improved outcome innovation inter-institutional interest investigator-initiated trial medical specialties meetings member multidisciplinary next generation novel patient oriented programs radiological imaging recruit resistance mechanism success targeted treatment tumor web site

Academic Medical Centers Advanced Malignant Neoplasm Advisory Committees Alabama Antineoplastic Agents Appointment Area Authorship Automobile Driving Award Basic Science Berlin Biology Breast Budgets Cancer Center Cancer Patient Catchment Area Cessation of life Clinical Cancer Center Clinical Investigator Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Collaborations Collection Communities Compassion Comprehensive Cancer Center Conduct Clinical Trials Country Data Death Rate Department chair Development Diagnosis Discipline Discipline of obstetrics Disease Early Detection Research Network Early Therapeutic-Clinical Trials Network Eastern Cooperative Oncology Group Education and Outreach Enrollment Ensure Faculty Funding Goals Grant Growth Gynecology Health Human Image Immunology Immunotherapy Incidence Infection Inflammation Informatics Infrastructure Institutes Institution Institutional Review Boards Jordan Kentucky Knowledge Lead Leadership Malignant Neoplasms Malignant neoplasm of pancreas Manuscripts Medical Medicine Mentors Mentorship Mission Mutation NCI Center for Cancer Research National Cancer Institute National Clinical Trials Network Obesity PD-1/PD-L1 PDL1 inhibitors Patient-Centered Care Patients Phase II/III Clinical Trial Physicians Prevention Prevention education Principal Investigator Process Protocols documentation Radiology Specialty Research Research Activity Research Personnel Research Priority Research Support Resource Sharing Resources Role Science Scientist Services Site System Technology Tennessee Time Tobacco use Training Translational Research Translations United States Universities Work cancer care cancer clinical trial cancer genomics cancer therapy data submission design drug discovery early phase trial evidence base gastrointestinal imaging science improved improved outcome innovation inter-institutional interest investigator-initiated trial medical specialties meetings member multidisciplinary next generation novel patient oriented programs radiological imaging recruit resistance mechanism success targeted treatment tumor web site

展开

项目摘要

PROJECT SUMMARY/ABSTRACT Vanderbilt-Ingram Cancer Center (VICC) is a matrix cancer center within Vanderbilt University Medical Center (VUMC). VICC has been part of the cooperative group system for over 27 years, and a Lead Academic Participating Site since the inception of the National Clinical Trials Network (NCTN). Throughout the years, we have integrated our physicians into leadership roles and our basic science into investigator-initiated trials, as well as enrolled patients onto clinical trials. Additionally, VICC has a long track record of leadership, both scientific and administrative, within the cooperative groups/NCTN, and helping junior faculty in clinical trial development. VICC brings great strengths to the NCTN, including two SPORE grants, an EDRN grant, a world class Institute of Imaging Science, eight highly funded scientific programs and an Early Therapeutics Clinical Trial Network (ETCTN) grant where successful early phase trials can be integrated into the NCTN. Our Personalized Cancer Medicine Initiative (PCMI) is dedicated to matching the appropriate therapy to the genetic changes, or mutations, that are driving the growth of cancers, with an active research component investigating mechanisms of resistance to targeted therapies. The key informatics of the VICC PCMI is MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations. With the development of PD-1/PD-L1 inhibitors and novel immune therapies on the horizon, VICC has recruited top researchers in immunology. Those top researchers in collaboration with other VUMC investigators created the Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) with an overall mission to train the next generation scientists and physicians and make fundamental discoveries in the areas of infection biology, immunology and inflammation with the goal of increasing knowledge and improving human health. VICC clinicians and scientists are academic leaders in their respective disciplines and will continue to significantly contribute to the NCTN goals with the objective to improve the outcomes for cancer patients. The VICC selected Dr. Jordan Berlin, MD, as Principal Investigator to continue leading the efforts of the institution to integrate its scientific, academic and patient resources into the NCTN. He has been involved extensively in the cooperative groups/NCTN in conduct of clinical trials, mentorship and leadership. To assist Dr. Berlin with the conduct of this grant, VICC created two advisory boards, Internal Advisory Board (IAB) and NCTN Executive Committee (NEC), whose membership includes a broad representation of medical disciplines and disease interests across VICC and VUMC. The IAB assures the optimal use of the grant, such as budget review, assuring multidisciplinary involvement, and participation throughout the NCTN. The NEC implements operational functions, such as trial opening, accrual and mentoring. Operationally, the NEC has actively managed NCTN trial opening, accruals and participation across disciplines and groups. Both the IAB and NEC work to integrate VICC science into the NCTN. The VICC Clinical Trials Shared Resource and its NCTN team ensures that regulatory, biospecimen, radiology and data submissions are timely and highly accurate. An extensive plan to further advance the integration of the NCTN into the VICC clinical research enterprise and VICC research into the NCTN is detailed in the grant, including the new appointment of Dr. Berlin to the role of Associate Director for Clinical Research Strategy and Shared Resources. This is a new role for VICC, designed to allow coordination of clinical research priorities across all VICC programs and to increase the translation of VICC science into clinical trials. For this grant, Dr. Berlin’s new role will help to strengthen the prioritization of NCTN trials across the institution.

项目摘要/摘要 Vanderbilt-Ingram癌症中心（VICC）是范德比尔特大学医学中心的基质癌症中心（VUMC）。 VICC已成为合作小组系统的一部分已有27年以上，并且是领导学者自国家临床试验网络（NCTN）成立以来，参与现场。这些年来，我们将我们的医师纳入领导角色和基础科学纳入研究人员发起的试验，并将患者纳入临床试验。此外，VICC的领导能力很长，两者都科学和行政，在合作团体/NCTN中，并帮助初级教师参加临床试验发展。 VICC为NCTN带来了巨大的优势，其中包括两个孢子赠款，一个Edrn Grant，一个世界班级成像科学研究所，八个高度资助的科学计划和一个早期的治疗临床试验网络（ETCTN）赠款，可以将成功的早期试验纳入NCTN。我们的个性化的癌症医学计划（PCMI）致力于将适当的疗法与通用疗法相匹配正在促进癌症生长的变化或突变，并进行了积极的研究组件研究对靶向疗法的抗性机制。 VICC PCMI的关键信息是miscergenome，一个网站，不仅会告知医生最新的癌症基因组学，而且还提供了试验的可用性肿瘤具有可作用的遗传改变的患者。随着PD-1/PD-L1抑制剂的发展 VICC和新型免疫室在地平线上招募了免疫学的顶级研究人员。那些顶研究人员与其他VUMC调查人员合作创建了范德比尔特感染研究所免疫学和炎症（VI4）的总体使命是培训下一代科学家和医师并在感染生物学，免疫学和注射领域中发现基本发现目的是增加知识并改善人类健康。 VICC临床医生和科学家是各自学科的学术领导者，并将继续为NCTN目标做出重大贡献目的是改善癌症患者的结局。 VICC选择了医学博士Jordan Berlin博士作为首席研究员，继续领导机构将其科学，学术和患者资源整合到NCTN中。他一直参与其中在合作团体/NCTN中广泛进行临床试验，指导和领导力。协助柏林博士在这笔赠款的情况下，VICC创建了两个咨询委员会，内部咨询委员会（IAB）和 NCTN执行委员会（NEC）的成员包括广泛的医学学科代表以及VICC和VUMC的疾病兴趣。 IAB假定赠款的最佳用途，例如预算在整个NCTN中进行审查，确保多学科的参与和参与。 NEC实施操作功能，例如试验，振作和心理。在操作上，NEC已积极跨学科和群体托管NCTN试验开放，应计和参与。 IAB和NEC都致力于将VICC科学整合到NCTN中。 VICC临床试验共享资源及其NCTN团队确保监管，生物循环，放射学和数据提交是及时且高度准确的。一个广泛的计划，以进一步将NCTN整合到VICC临床研究企业和 VICC对NCTN的研究在赠款中详细介绍了，包括柏林博士的新任命为角色临床研究策略副主任和共享资源。这是VICC的新角色，旨在允许在所有VICC计划中协调临床研究的重点，并增加将VICC科学翻译成临床试验。对于这笔赠款，柏林博士的新角色将有助于加强整个机构的NCTN试验的优先级。